Charles Farber

Charles Farber

Auto-generated profile, based on publicly available information

Charles Farber

Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
CFCharles Farber
Charles Farber
Dmitry KurouskiDmitry Kurouski
Dmitry Kurouski

1 June 2018 in Forensic Chemistry
Verified
Journal Article
Closed access
EHElizabeth Hager
Elizabeth Hager
CFCharles Farber
Charles Farber
Dmitry KurouskiDmitry Kurouski
Dmitry Kurouski

16 August 2021 in Frontiers in Plant Science
Verified
Journal Article
Open access
CFCharles Farber
Charles Farber
JBJohn S. Bennett
John S. Bennett
TDTianyi Dou
Tianyi Dou
YAYousef Abugalyon
Yousef Abugalyon
DHDillon Humpal
Dillon Humpal
Dmitry KurouskiDmitry Kurouski
Dmitry Kurouski
Stalk rot caused by Colletotrichum graminicola is a disease of worldwide importance. Stalk rot is difficult to detect at the early stages of infection because the fungus colonizes the tissues inside the maize stem. Current diagnostic methods are time-consuming, laborious, and destructive to the stem tissue. We utilized Raman spectroscopy to follow the development of stalk rot in three different maize genotypes grown either in the field or the greenhouse. We then used the acquired spectra to calibrate statistical models to differentiate amongst the different disease timepoints and the genotypes themselves. This non-invasive spectroscopic method enabled high-accuracy identification of stalk rot based on both stalk and leaf spectra. We additionally found that leaf spectra were favorable for identifying maize by genotype. Finally, we identified Raman bands that showed correlation with the sizes of stalk rot-associated lesions in the stems. We demonstrated that Raman spectroscopy is a viable tool for detection of stalk rot disease, as well as potent for the differentiation of maize genotypes.

5 June 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
CFCharles Farber
Charles Farber
LSLee Sanchez
Lee Sanchez
Dmitry KurouskiDmitry Kurouski
Dmitry Kurouski
Poison ivy (Toxicodendron radicans) is a forest understory plant that grows throughout the United States, Canada and Mexico. The plant contains urushiol oils, a mixture of pentadecylcatechols, that cause severe allergic reactions on skin including reddish inflammation, uncoloured bumps and blistering. Such allergic reactions develop within hours or days, which facilitates unknowing spread of the urushiol inside the house. This enables continuous contact with urushiol extending the length of time of the rash. It should be noted that apart from extensive washing with soap and cold water, there is no direct way to treat urushiol-induced allergic reactions. In these circumstances, the best practice is to avoid contact with the plant. However, differentiating poison ivy from other plants requires sophisticated botanical experience that is not possessed by a vast majority of people. To overcome this limitation, we developed a confirmatory, label-free, non-invasive and non-destructive approach for detection and identification of poison ivy. We show that using a hand-held Raman spectrometer, 100% accurate identification of this species can be performed in only one second. We also demonstrate that in combination with partial least square discriminant analysis (PLS-DA), Raman spectroscopy is capable of distinguishing poison ivy from more than fifteen different plant species, including weeds, grasses and trees. The use of a hand-held spectrometer on a motorized robotic platform or an unmanned aerial vehicle (UAV) can be used for automated surveillance of household and agricultural spaces enabling confirmatory detection and identification of this dangerous plant species.

20 June 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRuben A. Mesa
Ruben A. Mesa
MEMiklos Egyed
Miklos Egyed
ASAnita Szoke
Anita Szoke
ASAleksandr Suvorov
Aleksandr Suvorov
Andrew PerkinsAndrew Perkins
Andrew Perkins
CHClaire N. Harrison
Claire N. Harrison
LBA7006 Background: PAC is a potent JAK2 inhibitor without significant JAK1 inhibition with minimal myelosuppression in early-phase studies in MF. Methods: The efficacy and safety of daily oral PAC was compared to BAT (2:1 randomization stratified for risk and platelet count). The 10 endpoint was the proportion of ITT patients (pts) achieving ≥ 35% spleen volume reduction (SVR) at week (wk) 24 by centrally reviewed MRI or CT. Secondary endpoints included the proportion achieving ≥ 50% reduction in total symptom score (TSS) at wk 24 using the MPN Symptom Assessment Form. Results: Patients:327 were enrolled (PAC:220, BAT:107), 62% with 10 MF. Median time from diagnosis was 1.12 years (PAC 0.99, BAT 1.60): 32% and 15% had a platelet counts < 100,000/µL or 35% reduction in spleen volume at data cutoff. TSS composite V1 + V2 response rates were 24.5%for PAC vs. 6.5% for BAT (p<0.0001) by ITT, and were 40.9% vs. 9.9% in evaluable pts (p<0.0001). Efficacy with baseline cytopenias: In pts with <100,000 and <50,000 platelets/μ/L, the SVR rates were 16.7% for PAC vs. 0% for BAT (p=0.009), and 22.9% vs. 0% (p=0.045) by ITT and 23.5% vs. 0% (p=0.007) and 33.3% vs. 0% (p=0.037) in evaluable pts. In RBC transfusion dependent pts, 25.7% of PAC pts became RBC independent vs. 0% of BAT pts (p=0.043). Safety: The most common adverse events (AE) for PAC were diarrhea, nausea, and vomiting; (grade 3 were <5%, <1%, <1% respectively). Hematologic AEs were similar between PAC and BAT. Conclusions: This study demonstrated PAC was well tolerated and induced significant and sustained SVR and symptom control even in patients with severe thrombocytopenia. PAC therapy resulted in RBC transfusion independence in a significant proportion of pts. Clinical trial information: NCT01773187.

6 December 2014 in Blood
Verified
Journal Article
Open access
CYChristopher A. Yasenchak
Christopher A. Yasenchak
CFCharles M. Farber
Charles M. Farber
EBElizabeth Budde
Elizabeth Budde
SAStephen Ansell
Stephen Ansell
RARanjana Advani
Ranjana Advani
NBNancy L. Bartlett
Nancy L. Bartlett
Background Outcomes for patients with DLBCL have improved over the past decade, with the addition of rituximab to CHOP or CHOP-like multi-agent chemotherapy regimens improving the 3-year overall survival (OS) of patients by 10-16% compared to multi-agent chemotherapy alone (Coiffier 2002; Pfreundschuh 2010). However, patients with high-intermediate or high-risk disease have relatively poor outcomes with the standard RCHOP regimen (Ziepert 2010); in a recent prospective trial of intermediate- and high-risk DLBCL patients, complete response (CR) rate for RCHOP alone was 26% (Hainsworth 2011). Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate comprising the antibody cAC10, specific for human CD30, covalently attached to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Brentuximab vedotin has demonstrated compelling activity as a single agent in patients with relapsed or refractory DLBCL, even those with low CD30 expression (Bartlett 2013). This phase 2, randomized, open label study is designed to evaluate the antitumor activity and safety of brentuximab vedotin (1.2 or 1.8 mg/kg) when administered in combination with standard RCHOP chemotherapy (A+RCHOP) for the front-line treatment of patients with CD30-unselected high-intermediate/high-risk (standard IPI score 3–5 or age-adjusted IPI [aaIPI] score 2–3) DLBCL (ClinicalTrials.gov NCT01925612). Methods Patients were randomized to receive up to 6 cycles of either 1.2 or 1.8 mg/kg brentuximab vedotin administered IV on Day 1 of every 21-day cycle in combination with RCHOP; prednisone was administered orally on Days 1-5 of every 21-day cycle. Assessments included disease response per Cheson 2007, as evaluated by the investigator, surveillance of adverse events (AEs), physical examination findings, and laboratory testing. The primary endpoints for this study are the CR rate at the end of treatment (EOT) and the type, incidence, and severity of AEs. Key secondary endpoints include objective response rate (ORR), progression-free survival (PFS), and OS. Results At the time of the planned interim analysis, 33 patients were enrolled (17 patients, 1.2 mg/kg A+RCHOP; 16 patients, 1.8 mg/kg A+RCHOP). Median age for all patients was 66 years (range, 21 to 81). At baseline, 36% were high-risk (IPI 4-5, aaIPI 3) and 64% were high-intermediate risk (IPI 3, aaIPI 2). The majority of patients (73%) had Stage IV disease and 33% had an ECOG status of 2. At the time of interim analysis, a total of 12 patients (6 patients in each arm) had completed EOT. Across both dose levels, ORR was 92% (11/12), with 7 CRs (58%), 4 PRs (33%), and 1 PD. The patient with PD subsequently died. Patients with PR had a median reduction of baseline tumor size of 84% (range, 92% to 83%), as measured by SPD. The only patient with follow-up after EOT converted from PR to CR without subsequent therapy. Treatment-emergent AEs occurring in ≥30% of patients treated (26/33) were nausea, diarrhea, peripheral sensory neuropathy, fatigue, and decreased appetite. Grade 3 or higher events occurring in more than 2 patients were febrile neutropenia and neutropenia. Events of peripheral neuropathy occurred equally per arm (46%, 1.2 mg/kg A+RCHOP; 46% 1.8 mg/kg A+RCHOP) and were generally Grade 1 or 2 (15% and 23%, respectively); events were of similar grade across dose levels. The median time to onset of any grade of peripheral neuropathy was 6 weeks (range, 2 to 10 weeks). Five patients (19%) had dose reductions due to peripheral neuropathy and 3 patients (12%) had dose reductions due to febrile neutropenia. One patient who received 1.2 mg/kg A+RCHOP discontinued study drug due to an AE (thrombocytopenia). Conclusions At doses of 1.2 or 1.8 mg/kg, A+RCHOP exhibited manageable toxicity in the treatment of newly-diagnosed DLBCL; the incidence of peripheral neuropathy was similar to single-agent administration of brentuximab vedotin (Pro 2012, Younes 2012) and RCHOP alone (Rummel 2013, Flinn 2014). In 12 patients with response-assessable, high-intermediate and high-risk DLBCL, A+RCHOP showed encouraging antitumor activity, with an ORR of 92% and a CR rate of 58%.